Sign in
Not yet recruitingPhase 2

Finerenone for Premature Ovarian Insufficiency (POI)

Key facts

Who runs it
The University of Hong Kong-Shenzhen Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
46 people, planned
Started
15 Sept 2026
Expected to end
Sept 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Finerenone
  • Placebo
Record updated
11 September 2026

Who can take part

Age
18 years to 39 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age of women <40 years
  • Diagnosis of POI according to ESHRE 2024 guidelines, defined as:
  • Oligomenorrhea or amenorrhea for at least 4 months; and
  • Elevated FSH levels (≥25 mIU/mL) on a single measurement

Who cannot take part

  • Known hypersensitivity to Finerenone or any of its excipients
  • Severe uncontrolled systemic diseases (cardiovascular, hepatic, renal, or endocrine disorders) that may interfere with study participation
  • Active malignancy or history of hormone-dependent cancer
  • Known chromosomal abnormalities or clinically significant genetic syndromes associated with POI
  • Currently participating in another interventional trial

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Premature ovarian insufficiency

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is testing whether finerenone, a medicine currently used to protect the kidneys and heart, can help women with premature ovarian insufficiency (POI) grow ovarian follicles and produce eggs that can be collected for in vitro fertilization (IVF). Women with POI often have very few or no active egg-containing follicles, making it hard for them to conceive. About 46 women with POI will be randomly assigned, without either the participants or their doctors knowing the assignment, to take either finerenone or a matching placebo twice weekly for 24 weeks. Participants will be monitored regularly with ultrasound and blood tests. If follicle growth is observed, participants may undergo ovarian stimulation so that eggs or embryos can be collected and frozen. The main goal is to see whether more women in the finerenone group have eggs successfully retrieved during an IVF cycle, compared with the placebo group. The study will also look at other measures of ovarian reserve, egg and embryo quality, and pregnancy outcomes among participants who go on to embryo transfer.

The 2 groups in the trial

  • FinerenoneTreatment being tested

    Participants received oral finerenone 20 mg twice weekly for 24 weeks during the double-blind treatment phase.

  • PlaceboPlacebo, for comparison

    Participants received matching placebo tablets, oral, twice weekly for 24 weeks during the double-blind treatment phase.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Finerenone in Women With Premature Ovarian Insufficiency
Criteria questions
Built from NCT07815509, who can take part
Record updated
11 September 2026